These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32591776)

  • 21. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
    Peverelli E; Olgiati L; Locatelli M; Magni P; Fustini MF; Frank G; Mantovani G; Beck-Peccoz P; Spada A; Lania A
    Cancer Lett; 2010 Feb; 288(2):170-6. PubMed ID: 19619936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
    Cuevas-Ramos D; Fleseriu M
    J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.
    Zitzmann K; Andersen S; Vlotides G; Spöttl G; Zhang S; Datta R; Culler M; Göke B; Auernhammer CJ
    Neuroendocrinology; 2013; 98(2):128-36. PubMed ID: 23797089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
    Ferone D; Arvigo M; Semino C; Jaquet P; Saveanu A; Taylor JE; Moreau JP; Culler MD; Albertelli M; Minuto F; Barreca A
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1044-50. PubMed ID: 16046458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
    Zatelli MC; Ambrosio MR; Bondanelli M; Uberti ECD
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S29-S35. PubMed ID: 17413185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
    Ren SG; Kim S; Taylor J; Dong J; Moreau JP; Culler MD; Melmed S
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5414-21. PubMed ID: 14602782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
    Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
    J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
    Hubina E; Nanzer AM; Hanson MR; Ciccarelli E; Losa M; Gaia D; Papotti M; Terreni MR; Khalaf S; Jordan S; Czirják S; Hanzély Z; Nagy GM; Góth MI; Grossman AB; Korbonits M
    Eur J Endocrinol; 2006 Aug; 155(2):371-9. PubMed ID: 16868153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas.
    Kim J; Oh JH; Harlem H; Culler MD; Ku CR; Lee EJ
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):177-187. PubMed ID: 32207278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.